v3.26.3
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Operating expenses:    
Research, development, and clinical trial expenses, net $ 29,236,508 $ 21,270,678
General and administrative expenses 6,817,729 5,934,125
Total operating expenses 36,054,237 27,204,803
Operating loss (36,054,237) (27,204,803)
Financial income (expenses), net 601,461 114,511
Change in fair value of the warrant liability 298,734 758,364
Unrealized gain on short-term investment 92,227
Share of loss on equity investment (263,477) (224,212)
Net loss for the year (35,325,292) (26,556,140)
Net loss attributable to non-controlling interest (421,030) (244,273)
Net loss for the year attributable to BriaCell $ (34,904,262) $ (26,311,867)
Net loss per share attributable to BriaCell - basic $ (6.97) $ (62.19)
Net loss per share attributable to BriaCell - diluted $ (6.97) $ (62.19)
Weighted average number of shares used in computing net basic earnings per share of common shares 5,010,907 423,114
Weighted average number of shares used in computing net diluted earnings per share of common shares 5,010,907 423,114